
AtriCure (ATRC) Stock Forecast & Price Target
AtriCure (ATRC) Analyst Ratings
Bulls say
AtriCure is strategically positioned for growth with their innovative product line for Afib and LAA management, along with investment in differentiation and strong clinical development. The company has shown promising sales growth and expects further success with new product launches in Europe. While there are potential risks, AtriCure is confident in their outlook and has raised their revenue, EBITDA, and EPS estimates for the future.
Bears say
AtriCure is a medical device company that specializes in surgical treatments and therapies for atrial fibrillation and left atrial appendage management. While the company has strong potential for growth, increased competition and reimbursement pressure in key international markets may negatively impact its financials in the long run. The company's EV/sales multiple of 3.0x is below its peers, but this could be attributed to its lower revenue growth compared to its competitors.
This aggregate rating is based on analysts' research of AtriCure and is not a guaranteed prediction by Public.com or investment advice.
AtriCure (ATRC) Analyst Forecast & Price Prediction
Start investing in AtriCure (ATRC)
Order type
Buy in
Order amount
Est. shares
0 shares